Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. Dec 15, 2021; 13(12): 2129-2148
Published online Dec 15, 2021. doi: 10.4251/wjgo.v13.i12.2129
Published online Dec 15, 2021. doi: 10.4251/wjgo.v13.i12.2129
Table 1 Relationship between BRAFV600E mutation and clinicopathological parameters in colorectal cancer
Variable | Cases (%) | BRAFV600E mutation | P value | |
Yes (%) | No (%) | |||
Gender | ||||
Male | 18 (60) | 6 (60) | 12 (60) | 0.326 |
Female | 12 (40) | 4 (40) | 8 (40) | |
Age (yr) | ||||
≥ 65 | 10 (33.3) | 4 (40) | 6 (30) | 0.440 |
< 65 | 20 (66.7) | 6 (60) | 14 (70) | |
Location | ||||
Right colon | 9 (30) | 2 (20) | 7 (35) | 0.345 |
Left colon | 9 (30) | 5 (50) | 4 (20) | |
Rectum | 12 (40) | 3 (30) | 9 (45) | |
Mucous tissue | ||||
Positive | 6 (20) | 1 (10) | 5 (25) | 0.326 |
Negative | 24 (80) | 9 (90) | 15 (75) | |
Differentiated degree | ||||
High/moderate differentiation | 20 (66.7) | 3 (30) | 17 (85) | 0.005a |
Poor differentiation | 10 (33.3) | 7 (70) | 3 (15) | |
T stage | ||||
T2 | 4 (13.3) | 0 | 4 (20) | 0.211 |
T3 | 3 (10) | 2 (20) | 1 (5) | |
T4 | 23 (76.7) | 8 (80) | 15 (75) | |
TNM stage | ||||
I + II | 13 (43.3) | 2 (20) | 11 (55) | 0.074 |
III + IV | 17 (56.7) | 8 (80) | 9 (45) | |
Lymph node | ||||
Positive | 17 (56.7) | 8 (80) | 9 (45) | 0.074 |
Negative | 13 (43.3) | 2 (20) | 11 (55) | |
Nerve invasion | ||||
Positive | 7 (23.3) | 4 (40) | 3 (15) | 0.143 |
Negative | 23 (76.7) | 6 (60) | 17 (85) | |
Vessel carcinoma embolus | ||||
Positive | 3 (10) | 1 (10) | 2 (10) | 0.652 |
Negative | 27 (90) | 9 (90) | 18 (90) | |
CA19-9 (U/mL) | ||||
High | 12 (40) | 7 (70) | 5 (25) | 0.024a |
Normal | 18 (60) | 3 (30) | 15 (75) | |
CEA (ng/mL) | ||||
High | 11 (36.7) | 3 (30) | 8 (40) | 0.452 |
Normal | 19 (63.3) | 7 (70) | 12 (60) | |
PLT count (× 109/L) | ||||
High | 12 (40) | 5 (50) | 7 (35) | 0.344 |
Normal | 18 (60) | 5 (50) | 13 (65) |
Table 2 Relationship between BRAFV600E mutation and microvascular density/microlymphatic vessel density in colorectal cancer
BRAFV600E mutation | MVD | MLVD | ||
mean ± SD | P value | mean ± SD | P value | |
+ | 38.53 ± 17.11 | 0.030 | 9.67 ± 5.63 | 0.0001 |
- | 27.54 ± 9.54 | 3.81 ± 2.06 |
Table 3 Relationship between BRAFV600E mutation and tumor-associated macrophages in colorectal cancer
BRAFV600E mutation | CD68+ macrophage | CD163+ M2 macrophage | ||
mean ± SD | P value | mean ± SD | P value | |
+ | 18.43 ± 13.53 | 0.664 | 8.33 ± 5.93 | 0.040 |
- | 20.96 ± 15.34 | 3.67 ± 3.02 |
Table 4 Relationship between BRAFV600E mutation and cancer-associated fibroblasts in colorectal cancer
BRAFV600E mutation | CAFs | P value | |
Low expression (cases) | High expression (cases) | ||
+ | 2 | 8 | 1 |
- | 3 | 17 |
- Citation: Zhi J, Jia XJ, Yan J, Wang HC, Feng B, Xing HY, Jia YT. BRAFV600E mutant colorectal cancer cells mediate local immunosuppressive microenvironment through exosomal long noncoding RNAs. World J Gastrointest Oncol 2021; 13(12): 2129-2148
- URL: https://www.wjgnet.com/1948-5204/full/v13/i12/2129.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i12.2129